Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDC-0980 + paclitaxel is a combination of **apitolisib (GDC-0980)**, a dual inhibitor of **class I phosphatidylinositol 3-kinases (PI3K)** and **mammalian target of rapamycin (mTOR) kinases**, with **paclitaxel**, a microtubule-stabilizing chemotherapeutic agent. GDC-0980 blocks key intracellular signaling pathways (PI3K/mTOR) involved in cell growth and survival[1][4][5]. Paclitaxel disrupts microtubule dynamics, causing cell cycle arrest and apoptosis. This combination has been investigated for synergistic antitumor activity, primarily in **locally recurrent or metastatic breast cancer** and other solid tumors[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GDC-0980 + paclitaxel.